Context Therapeutics (CNTX) Preferred Stock Liabilities (2020 - 2021)
Context Therapeutics (CNTX) posted Preferred Stock Liabilities of $21.1 million for Q3 2021, up 232.18% sequentially from $6.3 million in Q2 2021, and up 232.18% YoY from $6.3 million in Q3 2020.
Context Therapeutics (CNTX) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Context Therapeutics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $21.1 million in Q3 2021.
- Quarterly Preferred Stock Liabilities rose 232.18% year-over-year to $21.1 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $21.1 million (up 232.18% YoY) and the FY2020 annual result came in at $7.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities grew to $21.1 million in Q3 2021 per CNTX's latest filing, from $6.3 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $21.1 million in Q3 2021 and troughed at $29000.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Context Therapeutics | 48.18 Mn | 48.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 21.06 Mn |
| Jun 30, 2021 | 6.34 Mn |
| Mar 31, 2021 | 29,000.00 |
| Dec 31, 2020 | 7.77 Mn |
| Sep 30, 2020 | 6.34 Mn |